Boston Scientific Corporation $BSX Shares Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 95.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 176,421 shares of the medical equipment provider’s stock after acquiring an additional 86,386 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Boston Scientific were worth $11,070,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp grew its holdings in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors grew its holdings in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Norges Bank bought a new stake in shares of Boston Scientific in the 4th quarter worth about $2,199,395,000. Finally, Morgan Stanley raised its stake in shares of Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $45.09 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm’s 50-day moving average price is $51.39 and its two-hundred day moving average price is $69.60. Boston Scientific Corporation has a 52-week low of $42.25 and a 52-week high of $109.50. The stock has a market capitalization of $67.01 billion, a P/E ratio of 18.86, a P/E/G ratio of 0.82 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BSX. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 price target on shares of Boston Scientific in a research report on Monday, May 18th. Canaccord Genuity Group lowered their price objective on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a report on Monday, June 1st. Barclays cut their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Truist Financial decreased their target price on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, June 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.